Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs


FDA Approves RotaTeq

On Friday, Merck received FDA approval for its new oral rotavirus vaccine, RotaTeq, and will begin domestic distribution within a week. At a cost of $187.50 for the three-dose series, RotaTeq is one of the most expensive vaccines to date; by 2009, the company forecasts that the vaccine could bring in as much as $500 million in annual revenue.

According to the New York Times:

Nuking Malaria

The latest issue of Business 2.0 features an article on Stephen Hoffman and his company Sanaria, which is working to develop a malaria vaccine by irradiating parasite-infected mosquitos.

How Sanaria turns the insects that transmit malaria into incubators for its vaccine:

Poverty and Development at Davos: From Celebrity Glitz to Quiet Action

What a difference a year can make! Davos 2005 had Bono and Sharon Stone among other glitterati talking about global poverty and global health, and featured at least three crowded plenary sessions on Africa, aid, AIDs, malaria and more -- with Tony Blair, Gordon Brown, Bill Gates and Jeffrey Sachs. It was 2005: the year of development announcements and commitments.

Davos Dispatch: Clinton's Biggest Worries

In my first dispatch from Davos, I observed that the atmosphere was upbeat. The business community is not worrying much about the dark predictions of the past year. There is, after all, still no collapse of the dollar despite the U.S. trade deficit; interest rates and inflation worldwide are low, and oil price increases are being easily absorbed. India and China are emerging as the new engines of growth and symbols of why market economies work.